RecruitingCOPDChronic Obstructive Pulmonary Disease
Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD
Eligible age
40–80 yrs
Accepts
All genders
Locations
8 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The dNerva Lung Denervation System is one-time treatment intended to improve breathing in Chronic Obstructive Pulmonary Disease (COPD) patients on standard medical care. The purpose of this study is to confirm the safety and efficacy of the Nuvaira Lung Denervation System in the treatment of COPD.
Sponsor: Nuvaira, Inc.
You may qualify if…
- ✓ ≥ 40 and ≤ 80 years of age at the time of consent.
- ✓ Women of childbearing potential must not be pregnant, evidenced by a negative pregnancy test (blood or urine) pre-treatment, or lactating and agree not to become pregnant for the duration of the study.
- ✓ Smoking history of at least 10 pack years.
- ✓ Not smoking or using any other inhaled substance (e.g. cigarettes, vaping, cannabis, pipes) for a minimum of 2 months prior to consent and agrees to not start for the duration of the study.
- ✓ Resting SpO2 ≥ 89% on room air.
- ✓ MMRC ≥ 2; CAT score ≥ 10.
- ✓ Diagnosis of moderate to severe COPD as defined by FEV1/FVC \< 70% (post-bronchodilator), 25% ≤ FEV1 ≤ 70% predicted, and PaCO2 \< 50 (if FEV1 \< 30%).
- ✓ RV ≥ 175% of predicted and RV/TLC \> 55% (post-bronchodilator).
You may not qualify if…
- ✕ Body Mass Index (BMI) \<18 or \>32.
- ✕ Participant has an implantable electronic device and has not received appropriate medical clearance.
- ✕ Uncontrolled diabetes in the opinion of the investigator.
- ✕ 4 or more respiratory related hospitalizations within 1 year of consent.
- ✕ Malignancy treated with radiation or chemotherapy within 1 year of consent.
- ✕ Participant diagnosed with a dominant non-COPD lung disease, or condition affecting the lungs, which is the main driver of the participant's clinical symptoms (e.g., cystic fibrosis, paradoxical vocal cord motion, eosinophilic granulomatosis with polyangiitis (EGPA), allergic bronchopulmonary aspergillosis, interstitial lung disease or active tuberculosis or Asthma) or has a documented medical history of pneumothorax within 1 year of consent.
- ✕ Clinically relevant bronchiectasis, defined as \> 1/3 cup mucous expectoration daily.
- ✕ Pre-existing diagnosis of pulmonary hypertension, clinical evidence of pulmonary hypertension (e.g., cardiovascular function impairment including peripheral edema) and mPAP ≥25 mmHg at rest by right heart catheterization (or estimated right ventricular systolic pressure \>50 mmHg by echocardiogram if no previous right heart catheterization).
Where it's recruiting
Alabama
Birmingham
Florida
Jacksonville
Michigan
Detroit
North Carolina
Salem
Ohio
Columbus
Pennsylvania
DuBois · Philadelphia · Pittsburgh
Virginia
Richmond
Wisconsin
Milwaukee
Source: ClinicalTrials.gov · NCT07051707 · last updated 2026-04-28